GILLIS JONATHAN sold $82K of MPLT
GILLIS JONATHAN (CAO and Interim CFO) sold 10,167 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 on 2026-10-15.
How this was made
The 30-second read
Why it matters
Traders may briefly reassess sentiment toward MPLT due to insider selling, but the filing does not include new guidance, trial results, contracts, or regulatory actions.
Market read
A small insider open-market sale is disclosed; it is more relevant for sentiment than for a tradable fundamental re-rating.
What to watch
The article provides only the sale details, not total insider holdings changes over time, tax/option exercise context, or whether other insiders sold/bought around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for MapLight Therapeutics, Inc.
Ticker impact
MapLight Therapeutics Form 4 shows CAO and Interim CFO GILLIS Jonathan sold 10,167 shares at $8.0800 on 2026-10-15.
Likely limited downside pressure or volatility as traders weigh insider selling, but impact should fade absent follow-on news.
The filing is a Form 4 insider transaction; while it can influence sentiment, the disclosed size ($82k) is small and there is no accompanying operational, financial, or regulatory development in the text.
Market effects
Minimal, as the disclosure is company-specific insider selling without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the SEC Form 4 insider sale by its CAO and Interim CFO.
- insiderGILLIS JONATHAN
CAO and Interim CFO who sold 10,167 shares on 2026-10-15.